Dr Reddy's Laboratories (DRL), the second largest pharmaceutical company
in India after Sun Pharmaceutical Industries, is surging ahead with
strong domestic sales as well as exports to overseas markets with clear
focus on research and development, expansion, alliances and new
products. After good financial performance in the first quarter ended
June 2015 as well as for full year 2014-15, DRL scrip moved up strongly
and touched its yearly high level at Rs.4084.95 with full market capitalization of over Rs.68,550
crore on the BSE. With 25.5 per cent equity holding with promoters and
37.8 per cent by foreign institutional investors, DRL share of Rs.5 each is crossed milestone of Rs.4000 on July 31, 2015.
Considering the changing healthcare scenario, DRL has changed its corporate brand identity recently with new logo which is an expression of empathy and dynamism. The new logo keeps patients at the center of everything that DRL does. The objective of the re-branding exercise is to derive a unifying, patient-centric approach, to meet new and daunting challenges that patients are facing.
DRL has posted satisfactory financial performance during the first quarter ended June 2015. Its consolidated net profit went up by 13.7 per cent to Rs.626 crore from Rs.550 crore in the corresponding period of last year. EBITDA improved by 12 per cent to Rs.990 crore. Its consolidated net sales increased by 6.8 per cent to Rs.3,758 crore from Rs.3,518 crore. EPS improved to Rs.36.71 from Rs.32.34 in the last period.
Considering the changing healthcare scenario, DRL has changed its corporate brand identity recently with new logo which is an expression of empathy and dynamism. The new logo keeps patients at the center of everything that DRL does. The objective of the re-branding exercise is to derive a unifying, patient-centric approach, to meet new and daunting challenges that patients are facing.
DRL has posted satisfactory financial performance during the first quarter ended June 2015. Its consolidated net profit went up by 13.7 per cent to Rs.626 crore from Rs.550 crore in the corresponding period of last year. EBITDA improved by 12 per cent to Rs.990 crore. Its consolidated net sales increased by 6.8 per cent to Rs.3,758 crore from Rs.3,518 crore. EPS improved to Rs.36.71 from Rs.32.34 in the last period.
No comments:
Post a Comment